Patents Assigned to Technion Research and Development Foundation
  • Patent number: 5860922
    Abstract: A method for determining a flow rate of a substance or a thermo-contrast agent in an object including a surface and an upstream region, and the method comprising the steps of (a) providing the upstream region with a thermo-contrast agent; (b) obtaining successive temperature readings of at least a part of the surface of the object; (c) generating a temperature response curve from the temperature readings; (d) extracting a parameter from the temperature response curve; and (e) determining the flow rate from the parameter.
    Type: Grant
    Filed: July 21, 1997
    Date of Patent: January 19, 1999
    Assignee: Technion Research And Development Foundation LTD.
    Inventors: Naama Gordon, Rafael Beyar, Samuel Sideman
  • Patent number: 5812993
    Abstract: A digital neural network architecture including a forward cascade of layers of neurons, having one input channel and one output channel, for forward processing of data examples that include many data packets. Backward cascade of layers of neurons, having one input channel and one output channel, for backward propagation learning of errors of the processed data examples. Each packet being of a given size. The forward cascade is adapted to be fed, through the input channel, with a succession of data examples and to deliver a succession of partially and fully processed data examples each consisting of a plurality of packets. The fully processed data examples are delivered through the one output channel. Each one of the layers is adapted to receive as input in its input channel a first number of data packets per time unit and to deliver as output in its output channel a second number of data packets per time unit.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: September 22, 1998
    Assignee: Technion Research and Development Foundation Ltd.
    Inventors: Ran Ginosar, Nitzan Weinberg
  • Patent number: 5807403
    Abstract: A medical anchor device for implantation into a bone of a patient includes a staple having a leading, bone-boring tip for self-tapping a hole, a trailing, driven end for receiving implanting force to self-tap and implant said staple into the bone of a patient, and an attached suture thread. The staple has a longitudinal axis which passes through the tip and the driven end, the longitudinal axis changing shape upon implantation of the staple into a bone. A method of treating a patient includes ejecting and implanting the staple comprising a suture thread secured thereto into a bone by self-tapping a hole in the bone and securing the suture thread to a portion of the body's anatomy.
    Type: Grant
    Filed: March 26, 1996
    Date of Patent: September 15, 1998
    Assignee: Technion Research and Development Foundation, Ltd.
    Inventors: Mordechai Beyar, Amnon Foux
  • Patent number: 5786390
    Abstract: The subject invention relates to pharmaceutical composition of R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 28, 1998
    Assignees: Teva Pharmaceutical Industries Ltd., Technion Research and Development Foundation Ltd.
    Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Tirtsah Berger-Paskin, Haim Yellin, Alex Veinberg
  • Patent number: 5764767
    Abstract: A method for reconstructing a secret, over a public communication channel, using a perfect t-out-of-n secret sharing scheme. The scheme having a dealer which utilizes a delivering procedure for privately delivering n secret shares of the secret along with n keys to n participants that are interlinked by the channel. The scheme further having a secret reconstructing procedure for being executed by selected recipient participants, for reconstructing the secret by utilizing self secret share of the recipient participant and l-1 secret shares of the other participants. The secret reconstructing procedure includes the following steps:(i) receiving over said public communication channel l-1 encoded secret shares from the l-1 participants, respectively;(ii) decoding each one of the l-1 encoded secret shares, thereby obtaining l-1 decoded secret shares; and(iii) reconstructing the secret from the l-1 decoded secret shares and from the self secret share of the recipient participant.
    Type: Grant
    Filed: August 21, 1996
    Date of Patent: June 9, 1998
    Assignee: Technion Research and Development Foundation Ltd.
    Inventors: Amos Beimel, Ben-Zion Chor
  • Patent number: 5744500
    Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: April 28, 1998
    Assignees: Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation Ltd.
    Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Haim Yellin, Alex Veinberg
  • Patent number: 5740682
    Abstract: A method for the recovery of fugitive volatile organic vapors which comprises the steps of: (a) compressing said vapors to a pressure of at least 200 kpa; (b) feeding the hot compressed vapors to the desorption step of a Heat-Mass-Exchange (HME) system; (c) cooling the effluent resulted from the desorption step to the ambient temperature and separating out the condensed liquid obtained and (d) feeding the residual cold vapor phase, after the separation of the condensed liquid, to the adsorption step of said HME system, thus recovering the fugitive organic vapors. According to a preferred embodiment, the compressed vapors resulted from step (b) are at a temperature in the range of between 80.degree. to 150.degree. C., which may be reached by an external heating and the effluent resulted from the desorption step (c) is cooled at a temperature of about 5.degree. C.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: April 21, 1998
    Assignees: Ram Lavie, Technion Research and Development Foundation Ltd.
    Inventor: Ram Lavie
  • Patent number: 5692510
    Abstract: Methods for determining the flow rate of a substance within an object by extracting and mathematically manipulating numerical parameters from a thermoimaging temperature response curve of the surface of the object. The methods of the present invention are suitable to determine coronary arteries flow rates and myocardial perfusion rates in open chest conditions.
    Type: Grant
    Filed: September 7, 1995
    Date of Patent: December 2, 1997
    Assignee: Technion Research And Development Foundation Ltd.
    Inventors: Naama Gordon, Rafael Beyar, Samuel Sideman
  • Patent number: 5689422
    Abstract: A converter for use with a constant speed vehicle cruise control system including a speedometer for generating a self speed signal representative of the self speed of the vehicle and a speed adjustment control responsively coupled to the speedometer for maintaining the self speed of the vehicle at a preset speed. The converter adapts the control system to a constant distance system, and comprises a rangefinder for generating a distance signal corresponding to the distance of the vehicle from a front vehicle, and a distance-dependent speed adjustment device coupled to the rangefinder and to the speedometer for generating a synthetic-speed signal corresponding to the set speed required for maintaining a predetermined distance between the two vehicles. A selector switch allows either the self speed or synthetic-speed signals to be connected to the speedometer of the cruise control system.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: November 18, 1997
    Assignee: Technion Research and Development Foundation Ltd.
    Inventors: Michael Heymann, Arie Feuer
  • Patent number: 5677161
    Abstract: The invention relates to a preparation exhibiting enzymatic activity, which preparation has the capability of delignifying wood pulp at a temperature of at least 65.degree. C. and a pH of at least 9. Further, the invention relates to a method of producing said preparation by aerobically fermentating a selected Bacillus stearothermophilus strain. Furthermore, the invention relates to two isolated Bacillus stearothermophilus strains and mutants and variants thereof. The invention also relates to applications of the preparation of the invention, namely to a process comprising treatment of wood pulp with a preparation according to the invention, and a wood pulp and a fluff pulp treated with a preparation according to the invention, and also a paper, a board and a fluff made from a wood pulp treated with a preparation according to the invention.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: October 14, 1997
    Assignees: Korsnas Aktiebolag, The Technion Research and Development Foundation Ltd., Ramot-University Authority for Applied Research and Industrial Development Ltd.
    Inventors: Eugene Rosenberg, Yuval Shoham
  • Patent number: 5667336
    Abstract: An automated furrow irrigation control method and system involves the initiation of an irrigation flow into an upstream end of a furrow at an initial water discharge rate; continuously or periodically sensing the progress of water flow along the furrow; continuously or periodically increasing the water discharge rate in response to the sensed progress of the water flow so as to ensure a substantially continuous flow in the furrow at a flow rate which lies substantially between .+-.30% of a constant value; sensing the arrival of the water flow at a downstream end of the furrow; reducing the water discharge rate in response to the sensed arrival of the water flow at the downstream end of the furrow; sensing the percolation of the water flow at the downstream end down to a predetermined depth; and terminating the irrigation flow in response to the sensed percolation.
    Type: Grant
    Filed: June 19, 1995
    Date of Patent: September 16, 1997
    Assignee: Technion Research and Development Foundation
    Inventor: Benjamin Zur
  • Patent number: 5599991
    Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, brain ischemia, a head trauma injury, a spinal trauma injury, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 4, 1997
    Assignees: Teva Pharmaceutical Industries Ltd., Technion Research and Development Foundation, Ltd.
    Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Haim Yellin, Alex Veinberg
  • Patent number: 5576353
    Abstract: R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: November 19, 1996
    Assignees: Teva Pharmaceutical Industries Ltd., Technion Research and Development Foundation, Ltd.
    Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Haim Yellin
  • Patent number: 5532415
    Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, brain ischemia, a head trauma injury, a spinal trauma injury, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.
    Type: Grant
    Filed: March 28, 1995
    Date of Patent: July 2, 1996
    Assignees: Teva Pharmaceutical Industries Ltd., Technion Research and Development Foundation Ltd.
    Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Tirtsah Berger-Paskin, Haim Yellin, Alex Veinberg
  • Patent number: 5519061
    Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, brain ischemia, a head trauma injury, a spinal trauma injury, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 21, 1996
    Assignees: Teva Pharmaceutical Industries Ltd., Technion Research and Development Foundation Ltd.
    Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Haim Yellin
  • Patent number: 5483968
    Abstract: A method and apparatus for analyzing the electrical activity of the heart by Body Surface Potential Mapping (BSMP) in which an array of electrodes are applied over the thoracic region of a subject's body for producing measurements of the electrical signals generated in the thoracic region, and the measurements are processed for indicating certain electrical events in the subject's body. The array of electrodes are utilized to measure only the times of crossing of the electrical signals over a preset threshold.
    Type: Grant
    Filed: May 21, 1992
    Date of Patent: January 16, 1996
    Assignee: Technion Research and Development Foundation Ltd.
    Inventors: Dan Adam, Ilia Vitsnudel, Shlomo Gilat, Samuel Sideman
  • Patent number: 5472695
    Abstract: The invention relates to the use of either an aqueous extract or an organic extract of the plant Thymus to prepare a pharmaceutical composition useful to inhibit the growth of Helicobacter pylori and the urease activity of Helicobacter pylori. In case of an aqueous extract, a minimum amount of 0.5 mg of the dry plant in the extract is required but the preferred amounts are above 1.2 mg. The aqueous extract may be used either as a drink, with or without additional ingredients, or transformed into a capsule or a paste. The invention also relates to in-vitro methods for inhibiting the growth of the urease activity of Helicobacter pylori.
    Type: Grant
    Filed: April 8, 1994
    Date of Patent: December 5, 1995
    Assignee: Technion Research and Development Foundation Ltd.
    Inventors: Itzhak Neeman, Mina Tabak, Robert Armon
  • Patent number: 5467123
    Abstract: Color image enhancement apparatus comprising apparatus for receiving signals representing a color image, image processing apparatus, employing the received signals, for image processing of the high spatial frequency chromatic components of a color image, and apparatus for providing a color image from the output of said image processing apparatus.
    Type: Grant
    Filed: June 1, 1993
    Date of Patent: November 14, 1995
    Assignee: Technion Research and Development Foundation, Ltd.
    Inventors: Yehoshua Y. Zeevi, Ran Ginosar, Wolf Stuart
  • Patent number: 5457133
    Abstract: R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.
    Type: Grant
    Filed: February 17, 1994
    Date of Patent: October 10, 1995
    Assignees: Teva Pharmaceutical Industries Ltd., Technion Research and Development Foundation Ltd.
    Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Tirtsah Berger-Paskin, Haim Yellin
  • Patent number: 5453446
    Abstract: R(+)-N-p-opargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (DAT), depression and the hyperactive syndrome.
    Type: Grant
    Filed: June 7, 1994
    Date of Patent: September 26, 1995
    Assignees: Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation Ltd.
    Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Tirtsah Berger-Paskin, Haim Yellin